Antimicrobial Susceptibility StudiesTigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011)
Introduction
Tigecycline was approved by the United States Food and Drug Administration (USA-FDA; 2005) for acute bacterial skin and skin structure infections and complicated intra-abdominal infections, and in 2009 for treatment of community-acquired bacterial pneumonia (Noskin, 2005, Tygacil Package Insert, 2011). Sentinel monitoring through surveillance programs, including the global SENTRY Antimicrobial Surveillance Program, has provided information on the continuing activity of tigecycline against antimicrobial-resistant Gram-positive and Gram-negative bacteria over time (Castanheira et al., 2010, Farrell et al., 2010, Mendes et al., 2008, Sader et al., 2011b).
The occurrence of multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria continues to increase. This problem has fostered recommendations from professional societies such as the Infectious Disease Society for America (IDSA) and governmental agencies to encourage the development of new antimicrobial agents (Boucher et al., 2009, IDSA, 2010). However, therapeutic options for the treatment of MDR pathogens remain limited as diverse regional and local resistance patterns evolve. In this study, the activity of tigecycline tested against resistant subsets of bacteria from the SENTRY Program was evaluated.
Section snippets
Materials and methods
A total of 22,005 unique clinical isolates were consecutively collected (2011) in North America (NA; 9232 isolates [42.0% of total]), Europe and Mediterranean region (EU; 6776 [30.8%]), Latin America (LA; 2016 [9.2%]) and Asia-Pacific region (APAC, 3981 [18.1%]). Countries sampled were USA and Canada in NA; Belgium, Czech Republic, France, Germany, Greece, Ireland, Israel, Italy, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Turkey, United Kingdom, and Ukraine in EU;
Results
The activity of tigecycline (MIC distributions) tested against resistant surveillance subsets of clinical bacteria collected worldwide and the corresponding susceptible subsets are summarized in Table 1. Tigecycline was highly active against Gram-positive organisms (MIC50, ≤0.03–0.06 μg/mL and MIC90, 0.06–0.12 μg/mL) and tigecycline MIC distributions for MRSA, VRE and penicillin-resistant S. pneumoniae were very similar to those of their susceptible counterparts. Among the Enterobacteriaceae
Discussion
The prevalence of resistance to key therapeutic antimicrobial agents continues to increase among the bacterial species most frequently isolated in the clinical settings; and infections caused by resistant organisms remain difficult to treat. Monitoring antimicrobial resistance through international, multicenter surveillance programs remains important to detect regional variations in resistance patterns and to guide empirical antimicrobial therapy. The SENTRY Program annually evaluates the
Acknowledgments
The authors would like to thank all participating centers worldwide for contributing isolates to this surveillance protocol. All co-authors are employees of JMI Laboratories who were paid consultants to Pfizer in connection with the development of this manuscript. Laboratory testing of clinical isolates was performed by JMI Laboratories via the SENTRY Antimicrobial Surveillance platform and funded by Pfizer Inc.
References (22)
- et al.
The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008)
J Infect
(2010) - et al.
Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010)
Diagn Microbiol Infect Dis
(2012) Clinical impact of antibiotic-resistant Gram-positive pathogens
Clin Microbiol Infect
(2009)- et al.
Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005–2009)
Diagn Microbiol Infect Dis
(2010) - et al.
Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers
Diagn Microbiol Infect Dis
(2008) - et al.
Susceptibility of Klebsiella spp. to colistin and polymyxin B: Results from the SENTRY Antimicrobial Surveillance Program (2006–2009)
Int J Antimicrob Agents
(2011) - et al.
Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005–2009)
Diagn Microbiol Infect Dis
(2011) - et al.
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
Clin Infect Dis
(2009) - et al.
High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality
Clin Microbiol Infect
(2012) - et al.
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program
Antimicrob Agents Chemother
(2008)